CLSD Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-26 | 2023 | George Lasezkay President and Chief Executive Officer | 547,200 | 0 | 0 | 273,874 | 15,080 | 1,538,627 |
| 2024-04-26 | 2022 | Thomas Ciulla Former Chief Medical Officer and Chief Development Officer | 430,000 | 0 | 101,288 | 150,500 | 16,705 | 936,284 |
| 2024-04-26 | 2023 | Thomas Ciulla Former Chief Medical Officer and Chief Development Officer | 59,745 | 0 | 0 | 0 | 85,401 | 363,500 |
| 2024-04-26 | 2022 | Charles A. Deignan Chief Financial Officer | 388,650 | 0 | 101,288 | 138,250 | 10,050 | 876,029 |
| 2024-04-26 | 2023 | Charles A. Deignan Chief Financial Officer | 409,000 | 0 | 0 | 148,876 | 10,800 | 854,406 |
| 2024-04-26 | 2022 | George Lasezkay President and Chief Executive Officer | 531,500 | 0 | 213,525 | 265,750 | 19,150 | 1,531,215 |
| 2023-04-28 | 2021 | George Lasezkay President and Chief Executive Officer | 516,000 | 36,000 | 562,403 | 267,675 | 16,320 | 2,340,969 |
| 2023-04-28 | 2021 | Thomas Ciulla Former Chief Medical Officer and Chief Development Officer | 412,000 | 14,500 | 413,531 | 149,608 | 13,658 | 1,825,420 |
| 2023-04-28 | 2022 | Thomas Ciulla Former Chief Medical Officer and Chief Development Officer | 430,000 | 0 | 101,288 | 150,500 | 16,705 | 936,284 |
| 2023-04-28 | 2021 | Charles A. Deignan Chief Financial Officer | 353,163 | 14,000 | 386,404 | 134,048 | 9,600 | 1,544,816 |
| 2023-04-28 | 2022 | Charles A. Deignan Chief Financial Officer | 388,650 | 0 | 101,288 | 138,250 | 10,050 | 876,029 |
| 2023-04-28 | 2022 | George Lasezkay President and Chief Executive Officer | 531,500 | 0 | 213,525 | 265,750 | 19,150 | 1,531,215 |
| 2022-04-29 | 2021 | Thomas Ciulla Chief Medical Officer and Chief Development Officer | 412,000 | 14,500 | 413,531 | 149,608 | 13,658 | 1,825,420 |
| 2022-04-29 | 2021 | George Lasezkay President and Chief Executive Office r | 516,000 | 36,000 | 562,403 | 267,675 | 16,320 | 2,340,969 |
| 2022-04-29 | 2020 | George Lasezkay President and Chief Executive Office r | 503,313 | 0 | 286,513 | 163,577 | 14,777 | 1,371,007 |
| 2022-04-29 | 2021 | Charles A. Deignan Chief Financial Officer | 353,163 | 14,000 | 386,404 | 134,048 | 9,600 | 1,544,816 |
| 2022-04-29 | 2020 | Charles A. Deignan Chief Financial Officer | 342,876 | 0 | 59,250 | 78,004 | 9,450 | 641,590 |
| 2022-04-29 | 2020 | Thomas Ciulla Chief Medical Officer and Chief Development Officer | 367,375 | 0 | 59,250 | 83,578 | 9,450 | 671,663 |
| 2021-04-28 | 2019 | Charles A. Deignan Chief Financial Officer | 332,890 | 0 | 105,264 | 106,000 | 9,300 | 661,207 |
| 2021-04-28 | 2020 | George Lasezkay President and Chief Executive Officer | 503,313 | 0 | 286,513 | 163,577 | 14,777 | 1,371,007 |
| 2021-04-28 | 2020 | Charles A. Deignan Chief Financial Officer | 342,876 | 0 | 59,250 | 78,004 | 9,450 | 641,590 |
| 2021-04-28 | 2019 | George Lasezkay President and Chief Executive Officer | 371,235 | 0 | 181,772 | 159,809 | 32,461 | 1,045,192 |
| 2021-04-28 | 2020 | Thomas Ciulla | 367,375 | 0 | 59,250 | 83,578 | 9,450 | 671,663 |
| 2020-04-29 | 2018 | Brion Raymond Former Chief Commercial Officer | 255,167 | 30,000 | 0 | 67,789 | 6,115 | 954,296 |
| 2020-04-29 | 2019 | Brion Raymond Former Chief Commercial Officer | 300,000 | 0 | 54,500 | 89,251 | 426,938 | 978,442 |
| 2020-04-29 | 2019 | George Lasezkay | 385,235 | 0 | 181,772 | 159,809 | 32,461 | 1,045,192 |
| 2020-04-29 | 2019 | Daniel H. White Former President and Chief Executive Officer | 162,884 | 0 | 0 | 0 | 1,003,323 | 1,381,713 |
| 2020-04-29 | 2018 | Daniel H. White Former President and Chief Executive Officer | 482,478 | 0 | 0 | 183,944 | 8,700 | 675,122 |
| 2020-04-29 | 2019 | Charles A. Deignan Chief Financial Officer | 332,890 | 0 | 105,264 | 106,000 | 9,300 | 661,207 |
| 2020-04-29 | 2018 | Charles A. Deignan Chief Financial Officer | 330,065 | 7,500 | 0 | 88,096 | 8,700 | 434,361 |
| 2019-04-26 | 2018 | Brion Raymond | 255,167 | 30,000 | 0 | 67,789 | 6,115 | 954,296 |
| 2019-04-26 | 2018 | Daniel H. White Former President and Chief Executive Officer | 482,478 | 0 | 0 | 183,944 | 8,700 | 675,122 |
| 2019-04-26 | 2017 | Daniel H. White Former President and Chief Executive Officer | 400,000 | 0 | 0 | 180,000 | 8,100 | 1,648,696 |
| 2019-04-26 | 2018 | Charles A. Deignan Chief Financial Officer | 330,065 | 7,500 | 0 | 88,096 | 8,700 | 434,361 |
| 2019-04-26 | 2017 | Charles A. Deignan Chief Financial Officer | 289,623 | 0 | 0 | 93,259 | 4,532 | 847,085 |
| 2018-04-27 | 2016 | Charles A. Deignan Chief Financial Officer | 257,500 | 30,000 | 0 | 93,505 | 0 | 1,241,144 |
| 2018-04-27 | 2016 | Glenn Noronha, Ph.D. Chief Scientific Officer | 286,365 | 30,000 | 0 | 98,963 | 0 | 1,106,846 |
| 2018-04-27 | 2017 | Daniel H. White President and Chief Executive Officer | 400,000 | 0 | 0 | 180,000 | 8,100 | 1,648,696 |
| 2018-04-27 | 2016 | Daniel H. White President and Chief Executive Officer | 334,750 | 50,000 | 0 | 167,375 | 0 | 2,609,645 |
| 2018-04-27 | 2017 | Charles A. Deignan Chief Financial Officer | 289,623 | 0 | 0 | 93,259 | 4,532 | 847,085 |
| 2018-04-27 | 2017 | Glenn Noronha, Ph.D. Chief Scientific Officer | 313,639 | 0 | 0 | 93,308 | 3,388 | 870,956 |
| 2017-04-28 | 2016 | Glenn Noronha, Ph.D. Chief Scientific Officer | 286,365 | 30,000 | 0 | 98,963 | 0 | 1,106,846 |
| 2017-04-28 | 2015 | Glenn Noronha, Ph.D. Chief Scientific Officer | 274,495 | 2,749 | 0 | 67,251 | 0 | 521,595 |
| 2017-04-28 | 2015 | Daniel H. White President and Chief Executive Officer | 325,000 | 11,250 | 0 | 113,750 | 0 | 680,063 |
| 2017-04-28 | 2016 | Daniel H. White President and Chief Executive Officer | 334,750 | 50,000 | 0 | 167,375 | 0 | 2,609,645 |
| 2017-04-28 | 2016 | Charles A. Deignan Chief Financial Officer | 257,500 | 30,000 | 0 | 93,505 | 0 | 1,241,144 |
| 2017-04-28 | 2015 | Charles A. Deignan Chief Financial Officer | 250,000 | 8,750 | 0 | 61,250 | 0 | 497,100 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
